Pfizer (PFE)

Trump tweets trigger major stock swings for companies like Tesla, Boeing, Pfizer. Democrats demand an investigation.

How does $740 in annual income sound?

The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million.

US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up to 250%. Bond yields down & Fed may cut rates.

The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red.

The large pharmaceutical company reported strong second-quarter earnings results.

Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock into a breakout.

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest trading volume and driving market activity.

Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc.

TSMC stock fall on news of suspected trade secrets theft at the semiconductor manufacturing powerhouse, a major player in the AI chip market.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.

Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.

Pfizer's second-quarter 2025 results exceeded expectations with a 10% revenue growth and an adjusted EPS of $0.78.

Pfizer posts better-than-expected Q2 earnings and sales, raises 2025 EPS outlook, and outlines $7.7 billion in cost-saving initiatives through 2027.

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around $9.53 billion, close to analysts’ estimates. Its non-GAAP profit of $1.76 per share was 9.2% above analysts’ consensus estimates.

Shares advanced within striking distance of their 50-day line.

It's been a roller-coaster ride for Pfizer's stock over the past half-decade.